Guy Neff

A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

Stephen A. Harrison, Pierre Bédossa, Cynthia D. Guy et al. · New England Journal of Medicine · 2024 · 1.4K citations · Full text

Rifaximin Treatment in Hepatic Encephalopathy

Nathan M. Bass, Kevin D. Mullen, Arun J. Sanyal et al. · New England Journal of Medicine · 2010 · 1.2K citations

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Interim Analysis, Metabolic Associated Steatohepatitis, Hepatology +7

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 438 citations

Fibrosis, Hepatology, Liver Physiology +9

Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial

Stephen A. Harrison, Rebecca Taub, Guy Neff et al. · Nature Medicine · 2023 · 348 citations · Full text